Sequential Treatment Escalation May Extend Survival for Patients With Waldenström Macroglobulinemia
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Sequential treatment escalation may improve the survival of patients with Waldenström macroglobulinemia, according to results from a recent study.
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
An abstract is unavailable.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.
An abstract is unavailable.
The OncoAlert Newsletter is now out for June 23-29, 2023